ABCA1 Agonist Reverses the ApoE4-Driven Cognitive and Brain Pathologies
The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Abstract
The allele ɛ4 of apolipoprotein E (apoE4) is the most prevalent genetic risk factor for Alzheimer's disease (AD) and is therefore a promising therapeutic target. Human and animal model studies suggest that apoE4 is hypolipidated; accordingly, we have previously shown that the retinoid X receptor (RXR) agonist bexarotene upregulates ABCA1, the main apoE-lipidating protein, resulting in increased lipidation of apoE4, and the subsequent reversal of the pathological effects of apoE4, namely: accumulation of Aβ42 and hyperphosphorylated tau, as well as reduction in the levels of synaptic markers and cognitive deficits. Since the RXR system has numerous other targets, it is important to devise the means of activating ABCA1 selectively. We presently utilized CS-6253, a peptide shown to directly activate ABCA1 in vitro, and examined the extent to which it can affect the degree of lipidation of apoE4 in vivo and counteract the associated brain and behavioral pathologies. This revealed that treatment of young apoE4-targeted replacement mice with CS-6253 increases the lipidation of apoE4. This was associated with a reversal of the apoE4-driven Aβ42 accumulation and tau hyperphosphorylation in hippocampal neurons, as well as of the synaptic impairments and cognitive deficits. These findings suggest that the pathological effects of apoE4 in vivo are associated with decreased activation of ABCA1 and impaired lipidation of apoE4 and that the downstream brain-related pathology and cognitive…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“peptide mimetics used to upregulate ABCA1 were shown to increase APOE4 lipidation and reduce Aβ deposition and cognitive deficits in APOE4 knock-in (but not APOE3 knock-in) plaque-depositing mice, indicating that directly targeting APOE lipidation is an effective therapeutic approach212”
From Multifaceted roles of APOE in Alzheimer disease (2024) · cites this paper as [212]
In the citing paper
“indicating that directly targeting APOE lipidation is an effective therapeutic approach212”
From Multifaceted roles of APOE in Alzheimer disease (2024) · cites this paper as [212]
In the citing paper
“Thus, using ABCA1 agonists allows ApoE4 lipidation and was shown to reduce ApoE4-mediated Aβ42 accumulation and tau hyperphosphorylation in hippocampal neurons, as well as rescue synaptic impairments and cognitive deficits in ApoE4-targeted replacement mice [87].”
From Apoe4 and Alzheimer’s Disease Pathogenesis—Mitochondrial Deregulation and Targeted Therapeutic Strategies (2023) · cites this paper as [87]
In the citing paper
“Thus, using ABCA1 agonists allows ApoE4 lipidation and was shown to reduce ApoE4-mediated Aβ42 accumulation and tau hyperphosphorylation in hippocampal neurons, as well as rescue synaptic impairments and cognitive deficits in ApoE4-targeted replacement mice [87].”
From Apoe4 and Alzheimer’s Disease Pathogenesis—Mitochondrial Deregulation and Targeted Therapeutic Strategies (2023) · cites this paper as [87]
In the citing paper
“Thus, using ABCA1 agonists allows ApoE4 lipidation and was shown to reduce ApoE4-mediated Aβ42 accumulation and tau hyperphosphorylation in hippocampal neurons, as well as rescue synaptic impairments and cognitive deficits in ApoE4-targeted replacement mice [87].”
From Apoe4 and Alzheimer’s Disease Pathogenesis—Mitochondrial Deregulation and Targeted Therapeutic Strategies (2023) · cites this paper as [87]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993) · Science · doi:10.1126/science.8346443 · Cited by 9,429 · cited 1×
“Genetic studies of sporadic Alzheimer’s disease (AD) and of families with late onset AD revealed that the allele APOE (cid:2) 4 (apoE4) is a genetic risk factor for AD [1–3].”
Association of apolipoprotein E allele ϵ4 with late‐onset familial and sporadic Alzheimer's disease
Saunders, A. M., Strittmatter, W. J., Schmechel, D., St. George-Hyslop, P. H., Pericak-Vance, M. A., Joo, S. H., Rosi, B. L., Gusella, J. F., Crapper-MacLachlan, D. R., Alberts, M. J., et al. (1993) · Neurology · doi:10.1212/wnl.43.8.1467 · Cited by 3,786
A PPARγ-LXR-ABCA1 Pathway in Macrophages Is Involved in Cholesterol Efflux and Atherogenesis
Chawla, A., Boisvert, W. A., Lee, C.-H., Laffitte, B. A., Barak, Y., Joseph, S. B., Liao, D., Nagy, L., Edwards, P. A., Curtiss, L. K., et al. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00164-2 · Cited by 1,347
ApoE Promotes the Proteolytic Degradation of Aβ
Jiang, Q., Lee, C. Y. D., Mandrekar, S., Wilkinson, B., Cramer, P., Zelcer, N., Mann, K., Lamb, B., Willson, T. M., Collins, J. L., et al. (2008) · Neuron · doi:10.1016/j.neuron.2008.04.010 · Cited by 876
APOLIPOPROTEIN E ALLELES AS RISK FACTORS IN ALZHEIMER'S DISEASE
Roses, M. D. (1996) · Annual Review of Medicine · doi:10.1146/annurev.med.47.1.387 · Cited by 707 · cited 1×
“:+9723 6409624;Fax:+97236406356;E-mail:dmichael@post.tau.ac.il. allele, which renders it the most prevalent genetic risk factor for AD [2].”
Astrocytes synthesize apolipoprotein E and metabolize apolipoprotein E-containing lipoproteins
Pitas, R. E., Boyles, J. K., Lee, S. H., Foss, D., & Mahley, R. W. (1987) · Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism · doi:10.1016/0005-2760(87)90295-5 · Cited by 693 · cited 1×
“…CS-6253 accumulates in the brain and co-localizes with astrocytes, which are enriched with ABCA1 and are the major source of brain apoE [15, 38, 39] was assessed immunohistochemically by double staining of the hippocampus utilizing the anti-CS-6253 Ab and an Ab directed at the astrocytic…”
LXRs control lipid-inducible expression of the apolipoprotein E gene in macrophages and adipocytes
Laffitte, B. A., Repa, J. J., Joseph, S. B., Wilpitz, D. C., Kast, H. R., Mangelsdorf, D. J., & Tontonoz, P. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.98.2.507 · Cited by 683
Alzheimer’s disease: the cholesterol connection
Puglielli, L., Tanzi, R. E., & Kovacs, D. M. (2003) · Nature Neuroscience · doi:10.1038/nn0403-345 · Cited by 677
Sullivan, P. M., Mezdour, H., Aratani, Y., Knouff, C., Najib, J., Reddick, R. L., Quarfordt, S. H., & Maeda, N. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.29.17972 · Cited by 575 · cited 1×
“[24].”
Strittmatter, W. J., Saunders, A. M., Goedert, M., Weisgraber, K. H., Dong, L. M., Jakes, R., Huang, D. Y., Pericak-Vance, M., Schmechel, D., & Roses, A. D. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.23.11183 · Cited by 474
Research works printed but not linked: 1
- Salomon-Zimri, 2015, Behavioral testing affects the phenotypic expression of APOE ɛ3 and APOE ɛ4 in targeted replacement mice and reduces the differences between them, Alzheimers Dement (Amst), 1, 127, 10.1016/j.dadm.2014.11.014 · DOI
Cited by
APOE and Alzheimer’s disease: Advances in genetics, pathophysiology, and therapeutic approaches
Serrano-Pozo, A., Das, S., & Hyman, B. T. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30412-9 · Cited by 1,037
ApoE in Alzheimer’s disease: pathophysiology and therapeutic strategies
Raulin, A.-C., Doss, S. V., Trottier, Z. A., Ikezu, T. C., Bu, G., & Liu, C.-C. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00574-4 · Cited by 756
“Peptide mimetics used to upregulate ABCA1 have been shown to increase apoE4 lipidation, and reduce Aβ, tau, and cognitive deficits in a mouse model [207].”
BackgroundApoE4: an emerging therapeutic target for Alzheimer’s disease
Safieh, M., Korczyn, A. D., & Michaelson, D. M. (2019) · BMC Medicine · doi:10.1186/s12916-019-1299-4 · Cited by 449
Self-citationYin, F. (2023) · The FEBS Journal · doi:10.1111/febs.16344 · Cited by 441
Apolipoprotein E in lipoprotein metabolism, health and cardiovascular disease
Marais, A. D. (2019) · Pathology · doi:10.1016/j.pathol.2018.11.002 · Cited by 382
Metadata
- Authors
- Boehm-Cagan, A., Bar, R., Liraz, O., Bielicki, J. K., Johansson, J. O., & Michaelson, D. M.
- Affiliations
- The Department of Neurobiology, The George S. Wise Faculty of Life Sciences, The Sagol School of Neuroscience, Tel Aviv University, Tel Aviv, Israel
- Tel Aviv University (IL)
- Lawrence Berkeley National Laboratory (US)
- Artery Therapeutics, Inc., San Ramon, CA, USA
- Corresponding author
- Michaelson, Daniel M.
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2016-10-04
- Volume
- 54
- Issue
- 3
- Pages
- 1219-1233
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W2516112233
- Cited by
- 116
- References
- 52
- Citations by year
- 2026: 2 · 2025: 17 · 2024: 19 · 2023: 11 · 2022: 15 · 2021: 16 · 2020: 11 · 2019: 8 · 2018: 4 · 2017: 11 · 2016: 2
- FWCI
- 6.70
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Alzheimer s Disease (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- ABCA1, APOE ε4
- MeSH terms
- Animals, Brain, Cognition Disorders, Male, Mice, Inbred C57BL, Mice, Transgenic, Peptides, Mice, Apolipoprotein E4, ATP Binding Cassette Transporter 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: ABCA1 Agonist Reverses the ApoE4-Driven Cognitive and Brain Pathologies. https://app.cochat.ai/papers/10.3233/jad-160467
- The paper
- Boehm-Cagan, A., Bar, R., Liraz, O., Bielicki, J. K., Johansson, J. O., & Michaelson, D. M. (2016). ABCA1 Agonist Reverses the ApoE4-Driven Cognitive and Brain Pathologies. Journal of Alzheimer's Disease. https://doi.org/10.3233/jad-160467
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.